$Recursion Pharmaceuticals, In

$Recursion Pharmaceuticals, Inc.(RXRX)$ view order details.@Trade Feed Decoder

RXRX

09-19 17:21

USRecursion Pharmaceuticals, Inc.

Side	Price \| Filled	Realized P&L
Sell Close	5.00 200	+2.48% Closed

Recursion Pharmaceuticals, Inc.

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
09-19
Trade Feed Decoder
This trade in Recursion Pharmaceuticals (RXRX) resulted in a modest +2.48% gain, suggesting a short-term risk-managed approach given the stock's biotech sector volatility. The decision to sell at $5 aligns with potential technical resistance levels or profit-taking behavior, as biotech stocks often face binary catalysts (e.g., trial data) that could justify swift exits. The limited gain percentage implies either conservative position sizing or tight stop-loss discipline, both prudent in high-risk sectors. While the profit appears small, it reflects awareness of RXRX's 52-week range ($4.18-$14.98), where locking gains near lower bounds might mitigate downside risk. The trade demonstrates situational adaptability rather than trend-chasing, though sector-specific risks remain paramount for such developmental-stage biotech plays.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":480254164341168,"tweetId":"480254164341168","gmtCreate":1758273707526,"gmtModify":1758273709544,"author":{"id":4113358555722592,"idStr":"4113358555722592","authorId":4113358555722592,"authorIdStr":"4113358555722592","name":"CP_93","avatar":"https://community-static.tradeup.com/news/353ac2647ace39ffeed65829dea43de8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":22,"starInvestorOrderShareNum":215,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":13.98,"showRor":true,"winRationPercentage":61.434978,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$Recursion Pharmaceuticals, Inc.(RXRX)$ view order details.@Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":42,"commentSize":1,"repostSize":28,"favoriteSize":0,"link":"https://ttm.financial/post/480254164341168","repostId":0,"isVote":1,"tweetType":1,"viewCount":1546,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["RXRX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4113358555722592","orderId":"40549829362978816","kind":"TRADE","symbol":"RXRX","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/RXRX","symbolName":"Recursion Pharmaceuticals, Inc.","market":"US","action":"SELL","currency":"USD","symbolLogo":"","showFilledQuantity":true,"nameCN":"Recursion Pharmaceuticals, Inc.","orderType":"LMT","filledQuantityFinal":200,"avgFillPrice":5,"createTime":1758273690,"filledQuantity":"200","filledQuantityScale":"0","openFlag":false,"side":"DEBIT","contractMajorDescription":"Recursion Pharmaceuticals, Inc.","contractExtraDescription":"RXRX","legs":[],"completedFlag":true,"orderPnl":{"realizedPnlPercent":0.0248,"realizedPnlByAveragePercent":0.0248},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":480276751376512,"commentId":"480276751376512","gmtCreate":1758279034933,"gmtModify":1758283040046,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":480254164341168,"objectIdStr":"480254164341168","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"This trade in Recursion Pharmaceuticals (RXRX) resulted in a modest +2.48% gain, suggesting a short-term risk-managed approach given the stock's biotech sector volatility. The decision to sell at $5 aligns with potential technical resistance levels or profit-taking behavior, as biotech stocks often face binary catalysts (e.g., trial data) that could justify swift exits. The limited gain percentage implies either conservative position sizing or tight stop-loss discipline, both prudent in high-risk sectors. While the profit appears small, it reflects awareness of RXRX's 52-week range ($4.18-$14.98), where locking gains near lower bounds might mitigate downside risk. The trade demonstrates situational adaptability rather than trend-chasing, though sector-specific risks remain paramount for such developmental-stage biotech plays.","text":"This trade in Recursion Pharmaceuticals (RXRX) resulted in a modest +2.48% gain, suggesting a short-term risk-managed approach given the stock's biotech sector volatility. The decision to sell at $5 aligns with potential technical resistance levels or profit-taking behavior, as biotech stocks often face binary catalysts (e.g., trial data) that could justify swift exits. The limited gain percentage implies either conservative position sizing or tight stop-loss discipline, both prudent in high-risk sectors. While the profit appears small, it reflects awareness of RXRX's 52-week range ($4.18-$14.98), where locking gains near lower bounds might mitigate downside risk. The trade demonstrates situational adaptability rather than trend-chasing, though sector-specific risks remain paramount for such developmental-stage biotech plays.","html":"This trade in Recursion Pharmaceuticals (RXRX) resulted in a modest +2.48% gain, suggesting a short-term risk-managed approach given the stock's biotech sector volatility. The decision to sell at $5 aligns with potential technical resistance levels or profit-taking behavior, as biotech stocks often face binary catalysts (e.g., trial data) that could justify swift exits. The limited gain percentage implies either conservative position sizing or tight stop-loss discipline, both prudent in high-risk sectors. While the profit appears small, it reflects awareness of RXRX's 52-week range ($4.18-$14.98), where locking gains near lower bounds might mitigate downside risk. The trade demonstrates situational adaptability rather than trend-chasing, though sector-specific risks remain paramount for such developmental-stage biotech plays.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/480254164341168"}